NL-OMON28755招募中不适用
Temozolomide in children with recurrent or refractory CNS tumors.
SKION (Stichting Kinder Oncologie); Schering Plough0 个研究点目标入组 54 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 54
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Age 3-18;
- •2. Pathology: PNET/high grade glioma
- •measurable tumor;
排除标准
- •Non conformation to inclusion criteria.
研究者
相似试验
已完成
不适用
Temozolomide in children with recurrent or refractory central nervous system (CNS) tumours [Temozolomide bij kinderen met een gerecidiveerde of refractaire centraal zenuwstelsel tumor]Glioma high grade, primitive neuroectodermal tumour (PNET)Malignant neoplasm of brainCancerISRCTN16192422Dutch Childhood Oncology Group (Stichting Kinder Oncologie [SKION]) (The Netherlands)54
已完成
2 期
Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory NeuroblastomaNeuroblastomaNCT00276679Children's Cancer and Leukaemia Group
尚未招募
2 期
se of romiplostim in children with cancers requiring high dose of chemotherapy, to accelerate platelet count recoveryCTRI/2023/02/049906Dr. SHIVAM BANSA
已完成
2 期
Multicombination Therapy of Temozolomide, Vincristine, and Interferon-beta with Radiotherapy for Malignant GliomaJPRN-UMIN000040599Department of Neurosurgery, Hirosaki University School of Medicine50
已完成
2 期
Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast CancerSoft Tissue SarcomaBreast CancerNCT00194766University of Washington35